madman
Super Moderator
Sigrid Carlsson, MD, Ph.D., MPH, Assistant Attending Epidemiologist at Memorial Sloan Kettering Cancer Center (MSKCC), discusses the current state of prostate cancer screening, focusing on PSA screening, risk calculators, biomarkers, and MRI. While not a perfect tool, PSA screening reduces prostate cancer mortality by 30% and is a useful prognosticator that can be combined with other screening tools.